JP2023531069A5 - - Google Patents
Info
- Publication number
- JP2023531069A5 JP2023531069A5 JP2022580122A JP2022580122A JP2023531069A5 JP 2023531069 A5 JP2023531069 A5 JP 2023531069A5 JP 2022580122 A JP2022580122 A JP 2022580122A JP 2022580122 A JP2022580122 A JP 2022580122A JP 2023531069 A5 JP2023531069 A5 JP 2023531069A5
- Authority
- JP
- Japan
- Prior art keywords
- tau
- patient
- pharmaceutical composition
- binding member
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063043872P | 2020-06-25 | 2020-06-25 | |
| US63/043,872 | 2020-06-25 | ||
| PCT/EP2021/067536 WO2021260193A1 (en) | 2020-06-25 | 2021-06-25 | Prevention of axonal damage using antibody binding to amyloid beta 1-42 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023531069A JP2023531069A (ja) | 2023-07-20 |
| JP2023531069A5 true JP2023531069A5 (enExample) | 2024-07-01 |
Family
ID=76662499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022580122A Pending JP2023531069A (ja) | 2020-06-25 | 2021-06-25 | アミロイドβ１－４２に結合する抗体を使用する軸索損傷の予防 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230287092A1 (enExample) |
| EP (1) | EP4171742A1 (enExample) |
| JP (1) | JP2023531069A (enExample) |
| KR (1) | KR20230026490A (enExample) |
| CN (1) | CN116547299A (enExample) |
| AU (1) | AU2021295605A1 (enExample) |
| BR (1) | BR112022026359A2 (enExample) |
| CA (1) | CA3187785A1 (enExample) |
| IL (1) | IL299215A (enExample) |
| TW (2) | TWI916375B (enExample) |
| WO (1) | WO2021260193A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| WO2024015951A2 (en) * | 2022-07-15 | 2024-01-18 | Seq Biomarque, Llc | Methods and materials for identifying biomarkers and/or pathways associated with alzheimer's disease |
| CN117624357B (zh) * | 2024-01-26 | 2024-03-22 | 南京诺唯赞医疗科技有限公司 | p-Tau 217特异性抗体及其在阿尔茨海默症辅助诊断试剂盒的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US151A (en) | 1837-03-25 | Spring-saddle | ||
| US5654A (en) | 1848-06-27 | Door-spring | ||
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
| US5503978A (en) | 1990-06-11 | 1996-04-02 | University Research Corporation | Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| ES2276405T3 (es) | 1995-06-02 | 2007-06-16 | Gilead Sciences, Inc. | Ligandos de oligonucleotidos de alta afinidad a pdgf. |
| US8481277B2 (en) * | 2007-08-21 | 2013-07-09 | Washington University | Alzheimer's diagnosis |
| KR102308915B1 (ko) | 2012-10-15 | 2021-10-06 | 메디뮨 리미티드 | 아밀로이드 베타에 대한 항체 |
| US9958460B2 (en) * | 2013-10-24 | 2018-05-01 | Nanosomix, Inc. | Biomarkers and diagnostic methods for Alzheimer's disease and other neurodegenerative disorders |
| SI3769781T1 (sl) | 2015-08-19 | 2023-06-30 | Astrazeneca Ab | Stabilna formulacija proti-IFNAR1 |
| AR107893A1 (es) * | 2016-03-15 | 2018-06-28 | Astrazeneca Ab | TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE |
| JP7177702B2 (ja) * | 2016-05-06 | 2022-11-24 | ナノソミックス・インコーポレイテッド | アルツハイマー病および他の神経変性障害のシナプスタンパク質バイオマーカーおよび鑑別診断 |
| JP6949102B2 (ja) * | 2016-08-09 | 2021-10-13 | イーライ リリー アンド カンパニー | 併用療法 |
| US12117456B2 (en) * | 2016-11-10 | 2024-10-15 | Brain Biomarker Solutions In Gothenburg Ab | Methods for detecting an individual as being at risk of developing a neurodegenerative disease |
| CN113853214A (zh) * | 2019-05-21 | 2021-12-28 | Ac免疫有限公司 | 抗Aβ疫苗治疗 |
-
2021
- 2021-06-25 TW TW110123285A patent/TWI916375B/zh active
- 2021-06-25 BR BR112022026359A patent/BR112022026359A2/pt unknown
- 2021-06-25 EP EP21735716.9A patent/EP4171742A1/en active Pending
- 2021-06-25 IL IL299215A patent/IL299215A/en unknown
- 2021-06-25 CA CA3187785A patent/CA3187785A1/en active Pending
- 2021-06-25 CN CN202180052963.4A patent/CN116547299A/zh active Pending
- 2021-06-25 AU AU2021295605A patent/AU2021295605A1/en active Pending
- 2021-06-25 TW TW115103567A patent/TW202619748A/zh unknown
- 2021-06-25 WO PCT/EP2021/067536 patent/WO2021260193A1/en not_active Ceased
- 2021-06-25 KR KR1020237002535A patent/KR20230026490A/ko active Pending
- 2021-06-25 JP JP2022580122A patent/JP2023531069A/ja active Pending
- 2021-06-25 US US18/011,965 patent/US20230287092A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008129080A (ru) | Средства и способы лечения опухолевых заболеваний | |
| JP2023548858A5 (enExample) | ||
| JP2018529634A5 (enExample) | ||
| KR20080042905A (ko) | 항-ｃｄ３ 항체 조제물 | |
| JP2023520516A5 (enExample) | ||
| US20230030950A1 (en) | Treatment of neurodegenerative diseases using ultrasound and amyloid-beta antibodies | |
| JP2019512472A5 (enExample) | ||
| KR20190077306A (ko) | 항-o2 항체 및 이의 용도 | |
| US20240398979A1 (en) | Compositions and Methods for Treating Dopamine Disorders | |
| KR20260020387A (ko) | 이중특이성 항-아베타/TfR 항체의 치료적 용도 | |
| JP6560808B2 (ja) | 抗（＋）メタンフェタミンモノクローナル抗体 | |
| US20220127346A1 (en) | Methods of Safe Administration of Anti-Tau Antibody | |
| CA3135181A1 (en) | Fusion constructs and uses thereof | |
| CA2946929A1 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| TW202233666A (zh) | 減少人類對象中之ｔａｕ的方法 | |
| US20240158486A1 (en) | ANTI-N3pGlu AMYLOID BETA ANTIBODIES AND USES THEREOF | |
| CA2946931A1 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| CN107249630A (zh) | 通过il‑20r的拮抗作用治疗慢性阻塞性肺疾病的急性加重 | |
| JP6692755B2 (ja) | アルツハイマー病（ａｄ）の処置および予防 | |
| US20240360215A1 (en) | Anti-cd19 antibody in the treatment of cns lymphoma | |
| TH2101002581A (th) | วิธีการทรีตโรคตาโปนจากไทรอยด์โดยใช้แอนติบอดีชนิด anti-fcrn | |
| US20140130191A1 (en) | Methods for treating immune-mediated diseases of the nervous system administering a compound comprising agents that inhibit prokineticin receptors activity | |
| HK40102408B (en) | Pharmaceutical composition containing anti-lag-3 antibody and application thereof | |
| WO2015165971A1 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| Hansen et al. | Recent patents in antibody engineering |